24/7 Clients Support
- 24/7
Customer Service
- ISO 9001
Certification Company
- WHO-GMP
Certified Company
LENVALIEVA 10MG is an Capsule medication used for treatment purposes. It is manufactured by Allieva Pharma Private Limited.
| Brand Name | LENVALIEVA 10MG |
|---|---|
| Composition | Lenvatinib Capsules 10mg |
| Manufacturer | Allieva Pharma Private Limited |
| Dosage Form | Capsule |
| Packaging | Btl (30 cap) |
| Country of Origin | India |
LENVALIEVA 10MG (Lenvatinib Capsules 10mg) is a widely used Capsule medicine manufactured by Allieva Pharma Private Limited. It is commonly prescribed for...
LENVALIEVA 10 MG (Lenvatinib Capsules 10 mg) is a prescription targeted anticancer medicine containing Lenvatinib 10 mg, an advanced multi-kinase inhibitor used for the treatment of several types of cancer. It is commonly prescribed for patients with thyroid cancer, liver cancer, kidney cancer, and endometrial cancer, helping to slow tumor growth, delay disease progression, and improve treatment outcomes.
Lenvatinib belongs to a class of medicines known as Tyrosine Kinase Inhibitors (TKIs). It works by blocking specific proteins involved in tumor growth and blood vessel formation. Cancer cells require a continuous blood supply to receive oxygen and nutrients needed for growth. LENVALIEVA 10 MG helps prevent the formation of new blood vessels that feed tumors, thereby limiting cancer progression.
Unlike conventional chemotherapy, which attacks rapidly dividing cells throughout the body, Lenvatinib specifically targets pathways involved in cancer growth and angiogenesis (blood vessel formation). This targeted approach has made it an important component of modern oncology treatment strategies.
LENVALIEVA 10 MG is commonly prescribed for:
The medicine may be used alone or in combination with other anticancer therapies depending on the patient's diagnosis, disease stage, and treatment goals.
Lenvatinib has become a valuable treatment option because it targets multiple pathways involved in cancer progression, helping improve disease control in patients with advanced cancers.
Manufactured according to stringent pharmaceutical quality standards, LENVALIEVA 10 MG is designed to provide consistent quality, safety, and therapeutic effectiveness.
Patients receiving Lenvatinib therapy require routine medical monitoring, including blood pressure assessments, liver function tests, kidney function evaluations, thyroid monitoring, and regular clinical examinations.
Due to its targeted mechanism and broad clinical applications, LENVALIEVA 10 MG plays an important role in modern cancer care worldwide.
LENVALIEVA 10 MG (Lenvatinib Capsules 10 mg) is primarily used for the treatment and management of several advanced cancers.
The medicine is widely prescribed for advanced thyroid cancers that no longer respond to radioactive iodine treatment.
Lenvatinib helps control thyroid cancer that continues to grow despite radioactive iodine therapy.
The medicine may be used in eligible patients with advanced liver cancer.
Doctors may prescribe Lenvatinib as part of treatment strategies for advanced kidney cancer.
The medicine may be used in combination therapy for certain advanced endometrial cancers.
Lenvatinib may be considered in selected cancer treatment programs.
The medicine helps delay disease progression and support ongoing cancer control.
Lenvatinib supports personalized treatment approaches in modern oncology.
Lenvatinib belongs to a class of medicines known as Tyrosine Kinase Inhibitors (TKIs).
LENVALIEVA works by:
This targeted mechanism helps suppress tumor development and improve treatment outcomes.
Like all medicines, LENVALIEVA 10 MG may cause side effects in some patients. The severity and frequency of side effects vary among individuals.
Elevated blood pressure is one of the most frequently reported side effects.
Patients may experience weakness and tiredness during treatment.
Digestive disturbances are commonly reported.
Reduced appetite may affect nutritional intake.
Some patients may experience weight reduction.
Mild to moderate nausea may occur.
Inflammation or ulcers inside the mouth may develop.
Musculoskeletal discomfort may occur during therapy.
The medicine may affect kidney function and require monitoring.
Seek immediate medical attention if you experience:
Patients should immediately contact their healthcare provider if serious symptoms occur.
The dosage of LENVALIEVA 10 MG (Lenvatinib Capsules 10 mg) should always be determined by a qualified oncologist.
Treatment recommendations vary according to the cancer being treated.
The severity and progression of cancer influence treatment planning.
Liver and kidney health may affect dosage decisions.
Doctors may adjust therapy based on effectiveness and tolerance.
Drug interactions may require dosage modifications.
Before starting treatment, inform your doctor if you have:
Patients should also disclose all prescription medicines, supplements, and herbal products they are currently taking to avoid potential drug interactions.
Pregnant and breastfeeding women should not use this medicine unless specifically advised by a healthcare professional.
It is used for the treatment of certain thyroid, liver, kidney, and endometrial cancers.
Lenvatinib is a targeted anticancer medicine that blocks multiple pathways involved in tumor growth and blood vessel formation.
No. It is a targeted therapy known as a tyrosine kinase inhibitor and works differently from traditional chemotherapy.
Yes. It is commonly prescribed for advanced thyroid cancer, particularly when radioactive iodine therapy is no longer effective.
Yes. High blood pressure is a common side effect and requires regular monitoring.
Yes. Blood pressure, kidney function, liver function, and other clinical assessments are important throughout therapy.
Yes. Depending on the cancer type, it may be prescribed alone or alongside other anticancer medicines.
Yes. This medicine should only be used under the supervision of qualified healthcare professionals experienced in oncology and targeted cancer treatment.